UDG has been the topic of several other reports. Peel Hunt reissued a buy rating on shares of Udg Healthcare in a research note on Wednesday, August 1st. Jefferies Financial Group raised shares of Udg Healthcare to a buy rating and decreased their price target for the stock from GBX 895 ($11.69) to GBX 890 ($11.63) in a research note on Thursday, August 9th. Royal Bank of Canada began coverage on shares of Udg Healthcare in a research note on Wednesday, November 7th. They issued an outperform rating and a GBX 800 ($10.45) price target on the stock. Barclays reissued an equal weight rating on shares of Udg Healthcare in a research note on Friday, September 28th. Finally, Numis Securities restated a reduce rating on shares of Udg Healthcare in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. Udg Healthcare currently has a consensus rating of Hold and a consensus price target of GBX 845.60 ($11.05).
LON:UDG opened at GBX 599 ($7.83) on Thursday. Udg Healthcare has a twelve month low of GBX 690 ($9.02) and a twelve month high of GBX 963 ($12.58).
About Udg Healthcare
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates through three segments: Ashfield, Sharp, and Aquilant.
Featured Story: How Investors Use a Balance Sheet
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.